Journal of Clinical and Cellular Immunology
Open Access

Novel negative selection marker CD54 enhances differentiation of human adipose-derived mesenchymal stem cells

2^nd International Conference on Clinical & Cellular Immunology

October 15-17, 2013 Hampton Inn Tropicana, Las Vegas, NV, USA

Basil M. Hantash, Longmei Zhao, Poria Abdollah, Sylvia Do and Chris Nye

Accepted Abstracts: J Clin Cell Immunol

Abstract :

Due to their multi-differentiation potential and immunosuppressive function, mesenchymal stem cells (MSCs) hold huge promise in regenerative medicine. Lack of specific selection markers to isolate MSCs renders their use at risk of fibroblast contamination. The aim of the study was to identify new surface protein markers that can be used for MSC purification during in vitro expansion. With real-time RT-PCR, we demonstrated that primary human dermal fibroblasts expressed CD54 mRNA 10-fold more than early passage human adipose-derived MSCs (AMSCs). Flow cytometry illustrated 88.0% � 4.1% of dermal fibroblasts strongly expressed CD54 on their surface with a mean fluorescence intensity ratio of 24.0 � 0.0 compared to 11.0% � 0.7% and minimal intensity for AMSCs. Evaluation of CD54 sorted AMSCs revealed CD73 expression was 2.2-fold higher in the CD54 - versus CD54 + fraction. CD54- AMSCs demonstrated increased adipogenic and osteogenic differentiation potential relative to CD54 + AMSCs. In conclusion, we identified CD54 as a novel selection marker capable of distinguishing MSCs from fibroblasts and thus enhancing MSC osteogenic and adipogenic differentiation potential.